The 20-core prostate biopsy protocol--a new gold standard?

Area of Science:

• Urology
• Oncology
• Diagnostic Imaging

Background:

• Prostate cancer diagnosis relies on prostate biopsy.
• Optimizing biopsy protocols is crucial for improving detection rates.
• Current protocols may miss clinically significant cancers.

Purpose of the Study:

• To evaluate the efficacy of a 20-core prostate biopsy protocol in enhancing prostate cancer diagnosis.
• To compare the diagnostic yield of 20-core versus 10-core biopsy strategies.
• To identify patient subgroups benefiting most from an increased core biopsy number.

Main Methods:

• A comparative study of two consecutive patient groups: 10-core biopsy (Group 1) and 20-core biopsy (Group 2).
• Patients had prostate-specific antigen (PSA) levels between 3-30 ng/ml and/or abnormal digital rectal examination.
• Multivariate analysis was used to compare diagnosis rates across PSA subgroups (3-<6, 6-<10, 10-30 ng/ml).

Main Results:

• The 20-core protocol yielded a higher positive biopsy rate (51.7%) compared to the 10-core protocol (39.7%).
• The 20-core protocol demonstrated significantly higher cancer detection across all PSA subgroups.
• Detection rates were 47.2% vs. 28.1% (PSA 3-<6 ng/ml), 40.5% vs. 36.1% (PSA 6-<10 ng/ml), and 69.8% vs. 39.7% (PSA 10-30 ng/ml).

Conclusions:

• A 20-core prostate biopsy protocol is more efficient for diagnosing prostate cancer than a 10-core protocol.
• The benefit of the 20-core protocol is most pronounced in patients with PSA levels of 3-6 ng/ml.
• Pathological examination of radical prostatectomy specimens is necessary to confirm tumor significance.